Table I.
Correlation of MBTD1 expression with clinicopathologic characteristics in patients with prostate cancer.
| TMA | TCGA | ||||||
|---|---|---|---|---|---|---|---|
| Clinical features | Case | Low, n (%) | High, n (%) | P-value | Case | x±s | P-value |
| Tissue | |||||||
| Cancer | 71 | 32 (45.1) | 39 (54.9) | 0.006b | 499 | 520.20±8.31 | <0.001b |
| Benign | 7 | 7 (100.0) | 0 (0.0) | 52 | 448.3±15.21 | ||
| Age, years | |||||||
| <60 | 12 | 7 (58.3) | 5 (41.7) | 0.536 | 201 (<60) | 533.67±209.88 | 0.189 |
| ≥60 | 66 | 32 (48.5) | 34 (51.5) | 296 (≥60) | 511.38±166.72 | ||
| PSA level | |||||||
| ≤4 | – | – | – | – | 413 | 520.59±179.19 | 0.023a |
| >4 | – | – | – | 27 | 605.62±289.09 | ||
| Gleason score | |||||||
| ≤7 | – | – | – | – | 291 | 502.56±178.27 | 0.011a |
| >7 | – | – | – | 206 | 545.60±192.93 | ||
| Pathological grade | |||||||
| ≤2 | 23 | 9 (39.1) | 14 (60.9) | 0.397 | – | – | – |
| >2 | 44 | 22 (50.0) | 22 (50.0) | – | – | ||
| Clinical stage | |||||||
| I–II | 44 | 26 (59.1) | 21 (40.9) | 0.003b | – | – | – |
| III–IV | 26 | 6 (23.1) | 20 (76.9) | – | – | ||
| Tumor invasion | |||||||
| T1-T2 | 46 | 26 (56.5) | 20 (43.5) | 0.012a | 351 | 497.24±171.27 | 0.110 |
| T3-T4 | 24 | 6 (25.0) | 18 (75.0) | 55 | 556.07±260.38 | ||
| Lymph node metastasis | |||||||
| N0 | 58 | 30 (51.7) | 28 (48.3) | 0.026a | 344 | 520.81±181.97 | 0.307 |
| N1 | 12 | 2 (16.7) | 10 (83.3) | 80 | 543.69±172.95 | ||
| Distant metastasis | |||||||
| M0 | 56 | 29 (51.8) | 27 (48.2) | 0.039a | 455 | 517.20±178.44 | <0.001b |
| M1 | 14 | 3 (21.4) | 11 (78.6) | 3 | 1041.11±691.26 | ||
‘−’ indicates a lack of the relevant information for patients in the cohort.
a
P<0.05
b
P<0.01. x±s, mean ± standard deviation; MBTD1, malignant brain tumor domain-containing protein 1; PSA, prostate-specific antigen; TCGA, The Cancer Genome Atlas database.